**Description**

The NRG1β: HER3 (ERBB3) Chemiluminescent Assay Kit is an ELISA-based assay designed to measure the binding between NRG1β (neuregulin-1β) and HER3 (human epidermal growth factor receptor 3, also known as ERBB3) for screening and profiling applications. The NRG1β: HER3 (ERBB3) Chemiluminescent Assay Kit comes with enough purified NRG1β (amino acids 2-246) and HER3 (amino acids 20-643) proteins, detection antibody, assay buffer, and detection reagent for 100 enzyme reactions.




*Figure 1. NRG1β: HER3 (ERBB3) Chemiluminescent Assay Kit schematic.*
A 96-well plate is coated with NRG1β protein. After coating and blocking, HER3 is added in an optimized assay buffer. Unbound HER3 is washed away, and the plate is incubated with a detection antibody. Finally, ELISA ECL substrate is added to produce chemiluminescence that can be measured using a chemiluminescence reader. The chemiluminescence signal is proportional to the efficacy of HER3 binding to NRG1β.

**Background**

HER3 (human epidermal growth factor receptor 3) is a transmembrane protein encoded by the ERBB3 gene. HER3 is broadly expressed in human tissues however, increased expression of HER3 has been linked to a variety of solid tumors including ovarian, breast, colon, and gastric cancers and correlates with decreased overall survival in colorectal cancer patients. HER3 has the unique property of being inherently catalytically inactive but still being able to participate in ligand binding, forming heterodimers with nearby receptors of the HER family. The formation of these dimers initiates a cascade of downstream signaling steps critical to cell proliferation. Neuroregulins (NRG) are polypeptide growth factors that bind to HER proteins, with NRG1 being the most studied of the four known proteins in this family. NRG1 specifically binds to HER3 and HER4. NRG1 binding induces dimerization of HER3 with HER2, transphosphorylation, and activation of several pathways such as the PI3K (phosphoinositide 3-kinase)/AKT signaling pathway. Due to HER3 cell surface expression in a variety of cancers and correlation with decreased survival, HER3 is a prospective therapeutic target for antibody-drug conjugate (ADC) development. It has been suggested that elevated levels of NRG1 in the TME (tumor microenvironment) can be considered as a predictive biomarker for the effectiveness of anti-HER3 antibody treatments in cancer. For example anti-HER3 monoclonal antibody, seribantumab, effectively inhibits tumor growth in preclinical models driven by NRG1 fusions. Current efforts are focusing on the development of anti-HER3 therapeutics that block the binding to NRG1, particularly allosteric, non-ligand competing anti-HER3 molecules. One such molecule, 9F7-F11, has resulted in reduced tumor growth in tumor xenografts, versus a ligand-competing anti-HER3 ligand.


Our products are for research use only, not for diagnostic or therapeutic use
BPS Bioscience • bpsbioscience.com • 858-202-1401 • support@bpsbioscience.com

**Applications**

Study complex formation and screen compounds and biologics that block the binding of NRG1β to HER3 for drug discovery and high throughput screening (HTS) applications.

**Supplied Materials**

| Catalog # | Name | Amount | Storage |
|---|---|---|---|
| | NRG1β 1 Protein, Human (HEK293)* | 2.5 µg | -80°C |
| 102230 | HER3, Avi-Tag, His-Tag* | 5 µg | -80°C |
| 82620 | 5x PP-02 Buffer | 4 ml | -20°C |
| | HRP-Labeled Detection Antibody 3 | 10 µl | -80°C |
| 79743 | Blocking Buffer 3 | 2 x 25 ml | +4°C |
| 79670 | ELISA ECL Substrate A (translucent bottle) | 6 ml | Room Temp |
| | ELISA ECL Substrate B (brown bottle) | 6 ml | Room Temp |
| 79837 | 96-well module plate | 1 | Room Temp |

**The concentration of the protein is lot-specific and will be indicated on the tube.*

**Materials Required but Not Supplied**

- 1x PBS (Phosphate Buffer Saline) Buffer
- PBST Buffer (1x PBS, containing 0.05% Tween-20)
- Luminometer or microplate reader capable of reading chemiluminescence
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform

**Storage Conditions**

This assay kit will perform optimally for up to **6 months** from date of receipt when the materials are stored as directed.

**Safety**

This product is for research purposes only and not for human or therapeutic use. This product should be considered hazardous and is harmful by inhalation, in contact with skin, eyes, clothing, and if swallowed. If contact occurs, wash thoroughly.

**Contraindications**

The NRG1β: HER3 (ERBB3) Chemiluminescent Assay Kit is compatible with up to 1% final DMSO concentration.

**Assay Protocol**

- All samples and controls should be performed in duplicate.
- The assay should include “Blank”, “Positive Control”, and “Test Inhibitor” conditions.
- We recommend maintaining the diluted protein on ice during use.
- For detailed information on protein handling please refer to Protein FAQs (bpsbioscience.com).



Our products are for research use only, not for diagnostic or therapeutic use
● bpsbioscience.com ● 858-202-1401 ● support@bpsbioscience.com

- We recommend using Seribantumab (#82613) or HER3, Fc Fusion, Avi-Tag Recombinant (#102228) as internal control. If not running a dose response curve for the control inhibitor, we recommend running the control inhibitor at 0.1X, 1X and 10X the $IC_{50}$ value shown in the validation data below.

**Step 1: Coat 96-well module**

1. Thaw NRG1β on ice. Briefly spin the tube containing the protein to recover its full content.
2. Dilute NRG1β protein to 0.5 ng/µl with PBS (50 µl/well).
3. Add 50 µl of diluted NRG1β to every well except "Blank" wells.
4. Add 50 µl of Blocking Buffer 3 to "Blank" wells.
5. Incubate at 4°C overnight.
6. Wash the plate three times using 200 µl of PBST Buffer per well.
7. Tap the plate onto clean paper towel to remove the liquid.
8. Block the wells by adding 200 µl of Blocking Buffer 3 to every well.
9. Incubate at Room Temperature (RT) for at least 90 minutes.
10. Wash the plate three times using 200 µl of PBST Buffer per well.
11. Tap the plate onto clean paper towel to remove the liquid.

**Step 2: Binding reaction**

1. Prepare 1x Assay Buffer by diluting 5x PP-02 Assay Buffer 5-fold with distilled water.
2. Add 20 µl of 1x Assay Buffer to every well.
3. Prepare the Test Inhibitor (5 µl/well): for a titration prepare serial dilutions at concentrations 10-fold higher than the desired final concentrations. The final volume of the reaction is 50 µl.

   3.1 If the Test Inhibitor is soluble in water, prepare a solution of the compound that is 10-fold higher than the final desired concentration using 1x Assay Buffer.

   For the positive and negative controls, use 1x Assay Buffer (Diluent Solution).

   ***OR***

   3.2 If the Test Inhibitor is dissolved in DMSO, prepare a solution of the compound in 100% DMSO that is 100-fold higher than the highest concentration of the serial dilution. Then dilute 10-fold with 1x Assay Buffer (at this step the compound concentration is 10-fold higher than the desired final concentration). The concentration of DMSO in the dilution is now 10%.


Our products are for research use only, not for diagnostic or therapeutic use
BPS Bioscience • bpsbioscience.com • 858-202-1401 • support@bpsbioscience.com

Prepare serial dilutions of the Test Inhibitor at concentrations 10-fold higher than the desired final concentrations using 10% DMSO in 1x Assay Buffer to keep the concentration of DMSO constant.

For positive and negative controls, prepare 10% DMSO in 1x Assay Buffer (vol/vol) so that all wells contain the same amount of DMSO (Diluent Solution).

*Note: The final concentration of DMSO should not exceed 1%.*

4. Add 5 µl of Test Inhibitor to each well labeled as "Test Inhibitor".
5. Add 5 µl of Diluent Solution to the "Positive Control" and "Blank" wells.
6. Thaw HER3 on ice. Briefly spin the tube containing the protein to recover its full content.
7. Dilute HER3 to 2 ng/µl with 1x Assay Buffer (25 µl/well).
8. Add 25 µl of diluted HER3 to all wells.
9. Incubate at RT for 1 hour.

| | **Blank (non-coated wells)** | **Positive Control** | **Test Inhibitor** |
|---|---|---|---|
| 1x Assay Buffer | 20 µl | 20 µl | 20 µl |
| Test Inhibitor | - | - | 5 µl |
| Diluent Solution | 5 µl | 5 µl | - |
| Diluted HER3 (2 ng/µl) | 25 µl | 25 µl | 25 µl |
| **Total** | **50 µl** | **50 µl** | **50 µl** |

10. Wash the plate three times with 200 µl of PBST Buffer per well and tap the plate onto clean paper towel.

**Step 3: Detection**

1. Dilute 1000-fold the HRP-labeled Detection Antibody 3 with Blocking Buffer 3 (50 µl/well).
2. Add 50 µl of diluted HRP-labeled Detection Antibody 3 to every well.
3. Incubate for 60 minutes at RT.
4. Wash the plate three times with 200 µl of PBST Buffer per well and tap the plate onto clean paper towel.
5. Just before use, mix 1 volume of ELISA ECL Substrate A and 1 volume of ELISA ECL Substrate B (100 µl of mix/well).
6. Add 100 µl of mix to every well.
7. Immediately read the plate in a luminometer or microtiter-plate reader capable of reading chemiluminescence.


Our products are for research use only, not for diagnostic or therapeutic use
BPS Bioscience • bpsbioscience.com • 858-202-1401 • support@bpsbioscience.com

8. The "Blank" value should be subtracted from all other values.

**Reading Chemiluminescence**

Chemiluminescence is the emission of light (luminescence) which results from a chemical reaction. The detection of chemiluminescence requires no wavelength selection because the method used is emission photometry and is not emission spectrophotometry.

To properly read chemiluminescence, make sure the plate reader is set for LUMINESCENCE mode. Typical integration time is 1 second, delay after plate movement is 100 msec. Do not use a filter when measuring light emission. Typical settings for the Synergy 2 BioTek plate reader are: use the "hole" position on the filter wheel; Optics position: Top; Read type: endpoint. Sensitivity may be adjusted based on the luminescence of a control assay without enzyme (typically we set this value as 100).

**Example Results**




*Figure 2: Inhibition of NRG1β: HER3 binding by Seribantumab and HER3, Fc-Fusion, Avi-Tag Recombinant.*
HER3 was incubated with increasing concentrations of Seribantumab (#82613) or HER3, Fc-Fusion, Avi-Tag Recombinant (#102228) in an NRG1β-coated plate. Luminescence was measured using a Bio-Tek microplate reader. Results are expressed as a percentage of binding in which the condition without competitor is set to 100%.

*Data shown is representative. For lot-specific information, please contact BPS Bioscience, Inc. at support@bpsbioscience.com.*

**References**

Le Clorennec C., *et al.*, 2017 *Mol Cancer Ther* 16(7):1312-1323.
Beji A., *et al*., 2012 *Clin Cancer Res.* 18(4):956-68.

**Troubleshooting Guide**

Visit bpsbioscience.com/assay-kits-faq for detailed troubleshooting instructions. For all further questions, please email support@bpsbioscience.com

**Related Products**

| *Products* | *Catalog #* | *Size* |
|---|---|---|
| HER3 CHO Cell Line | 82299 | 2 vials |
| HER3 (E928G), GST-Tag Recombinant | 101645 | 20 µg/50 µg |
| HER3, GST-Tag Recombinant | 101646 | 20 µg/50 µg |
| NRG1β: HER4 (ERBB4) Binding Chemiluminescent Assay Kit | 82614 | 96 reactions |
| Chemi-Verse™ HER4 Kinase Assay Kit | 82553 | 96 reactions |
| Chemi-Verse™ HER2 Kinase Assay Kit | 82552 | 96 reactions |

*Version 081324*



Our products are for research use only, not for diagnostic or therapeutic use
● bpsbioscience.com ● 858-202-1401 ● support@bpsbioscience.com